In a blog for PharmaBoardroom, Thomas Cueni shares his views on the innovative pharmaceutical industry’s role in bringing critical solutions to accelerate progress toward UHC, from lab to the last mile.
Read more
Since antibiotics were discovered nearly a century ago, the rate of resistance growth is outpacing the rate at which new ones can be developed and be used against infections. If we lose this race, patient deaths will significantly increase from the current 1.2 million per year. The pharmaceutical industry recognized the impending crisis and set...
Read more
On 27 April 2023, IFPMA and OPPI issued an open letter to Health Ministers of the G20, highlighting the innovative pharmaceutical industry support for G20 health priorities.
Read moreDuring the pandemic, vaccines were at the top of the news agenda and at the forefront of people’s minds like never before. Scientists were celebrated on magazine covers, and vaccine makers became household names. The largest vaccination campaign in history helped to save millions of lives, protecting people from serious illness and helping our world...
Read more
On 24 April, IFPMA delivered a statement at the 24th WHO Expert Committee Meeting on the Selection and Use of Essential Medicines, held from 24-28 April 2023.
Read moreThe innovative pharmaceutical industry stands together with other members of the global health community to support countries in accelerating their efforts to achieve UHC. Read our position paper.
Read more
Every year during World Immunization Week we take the time to celebrate the impact of vaccines, but this year there is heightened concern and apprehension around the status of vaccination programs around the world. The big catch-up year Recent pandemic disruptions to health and education systems have led to significant drops in childhood vaccination numbers,...
Read more
On 17 April, IFPMA delivered a statement at the third meeting of the Working Group on Amendments to the International Health Regulations (2005) held from 17-20 April 2023.
Read moreCEOs met with Japanese Prime Minister Fumio Kishida and other officials in Japan, presenting the Tokyo Statement, which outlined top priorities for addressing global health challenges. They also discussed the importance to strengthen the innovation ecosystem in Japan and proposed establishing a strategic dialogue platform to enhance Japan's leadership position in the life science sector by fostering innovation that benefits both patients and economic growth.
Read more
The WHO Essential Medicines List (EML) is an important tool in global health and supports the achievement of the UN Sustainable Development Goals. IFPMA has published perspectives from the R&D-based industry on the utility and scope of the EML. This position paper represents IFPMA's perspective as of April 2023, ahead of the publication of the revised version of the EML.
Read moreIn a joint position paper, EFPIA, IFPMA and Vaccines Europe urge all countries to adopt a ‘multiple-site-to-one-license’ approach for registrations, in line with WHO and other guidelines. This will result in a reduction of duplicate work for all stakeholders, help to build agility and speed in supply chain management and improve patient access to medicines and vaccines.
Read moreThis month, I had the priviledge to return to Kigali, Rwanda after the launch of the State of UHC in Africa Report to witness next steps toward the delivery of health services for all. Since the report’s launch in 2021, Amref Health Africa has been working behind the scenes to develop the UHC Delivery Lab....
Read more